🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — July 10, 2026

The 11 filings for the period ending July 10, 2026, reveal a bifurcated market where a few large-cap companies like Delta Air Lines are experiencing strong top-line growth but significant margin compression due to surging input costs (fuel up 67% YoY), while a cluster of micro-cap and pre-revenue companies show nascent signs of revenue generation and cost control, albeit from extremely low bases. A dominant theme is the prevalence of going-concern risks and reliance on non-recurring gains, with 4 out of 11 companies (Radiant Strategies, Lottery.com, Sentinel Holdings, EvoAir) reporting accumulated deficits or negative equity. Insider trading activity was notably absent across all filings, which is a neutral signal but removes a key sentiment gauge. Capital allocation is minimal, with no dividends or buybacks reported, and most companies are in cash preservation or capital-raising modes. The most actionable intelligence comes from the stark contrast between Delta's operational scale and the micro-cap turnaround stories, where the latter show potential for significant revenue growth but carry extreme balance sheet risk.

11 high priority 11 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 10, 2026

This digest of 7 proxy filings reveals a governance landscape dominated by routine director elections and auditor ratifications, but with several high-materiality events that demand investor attention. The most significant development is Modine Manufacturing's pending Reverse Morris Trust transaction with Gentherm, which will reshape its corporate structure and trigger executive departures, including the retirement of Climate Solutions President Eric McGinnis. Aardvark Therapeutics stands out with a potentially dilutive stock option repricing proposal that could signal management's attempt to retain talent or align incentives after a period of underperformance. Lion Copper & Gold's proposed 20:1 to 30:1 share consolidation and quorum increase suggest the company is addressing a low stock price and potential governance vulnerabilities. Insider ownership data from Nexalin Technology shows concentrated insider control at 16.94%, while Dynatrace and Elite Express present standard governance proposals with no material financial disclosures. The overall theme is one of corporate restructuring and governance adjustments, with Modine and Aardvark presenting the most actionable insights for investors.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 10, 2026

The IPO pipeline on July 10, 2026, is dominated by a wave of S-1 filings from companies in transition—reverse mergers, SPAC combinations, and pivots into digital assets and AI—rather than traditional growth IPOs. A clear theme is the prevalence of resale registrations (6 of 11 filings) that offer no primary capital to issuers, creating significant share overhang and dilution risk for investors. Period-over-period data reveals a stark contrast: Apnimed's revenue surged 2,636% YoY from a related-party deal, while Holtec Nuclear saw a 7.0% revenue decline and a $23.7M operating loss at its Palisades segment. Capital allocation is uniformly non-existent, with no dividends or buybacks across the cohort, and insider activity is absent from all filings. The most critical development is the convergence of digital asset strategies—Avalanche Treasury (SPAC + crypto) and iPower (bitcoin/ethereum treasury)—signaling a new wave of crypto-exposed public entities, albeit with pre-revenue or untested models. Overall, the pipeline is heavy on risk and dilution, with few clear bullish catalysts, making selective, catalyst-driven scrutiny essential.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — July 10, 2026

On July 10, 2026, four micro-cap companies filed 8-Ks disclosing Nasdaq non-compliance, creating a concentrated wave of delisting risk in the small-cap space. All four filings are negative in sentiment, with materiality scores ranging from 8/10 to 9/10, signaling a systemic pattern of distress among low-priced equities. GeoVax Labs (GOVX) faces a stockholders' equity deficiency, while NanoVibronix (FEED), Lakeside Holding (LSH), and Mercer International (MERC) all violate the minimum $1.00 bid price rule. Notably, NanoVibronix is ineligible for the standard 180-day cure period due to a prior reverse split, making it the most acute risk. The concentration of these filings on a single day suggests a potential Nasdaq compliance sweep or broader market pressure on micro-cap stocks. No period-over-period financial trends, insider activity, or capital allocation data were available in these filings, limiting quantitative cross-comparison but highlighting the purely regulatory nature of the risk. The key market implication is a potential wave of delistings that could compress valuations across the micro-cap sector and trigger forced selling by index funds.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 10, 2026

The 32 filings for July 10, 2026, reveal a heightened period of executive and director turnover across US-listed companies, with 14 departures or resignations and 10 appointments or transitions. The most critical development is at ZyVersa Therapeutics, where the CEO and CFO are taking voluntary pay cuts and the company is exploring a 'going dark' strategy, signaling severe financial distress. Ategrity Specialty Insurance stands out with a positive signal, pre-announcing record Q2 results with >22% YoY growth and a new CFO appointment. The period-over-period comparisons are limited in these filings, but the data shows a clear pattern of leadership instability in small-cap and micro-cap companies, with several departures citing personal reasons or planned transitions. Insider activity is minimal, but the compensation changes at KBR and Team Inc. indicate a focus on retention and severance adjustments. Overall, the digest highlights a cautious environment with pockets of opportunity in companies like Ategrity and Axon Enterprise, which are strengthening their boards with experienced executives.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 10, 2026

The July 10, 2026, board room change digest reveals a period of significant leadership transition across 32 US-listed companies, with a notable concentration of CFO and C-suite departures and appointments. The most critical development is the severe financial distress at **ZyVersa Therapeutics**, where a director resigned and management is considering going dark, divesting assets, and cutting headcount. Conversely, **Ategrity Specialty Insurance** provides a strong counterpoint, pre-announcing record Q2 results with >22% premium growth and >75% net income growth, alongside a CFO transition. A pattern of planned retirements and transitions is evident at **Adient**, **Sterling Infrastructure**, and **Lee Enterprises**, while companies like **KBR** and **Team Inc.** are proactively adjusting executive severance policies. The data shows a mix of routine board refreshment (e.g., **Alpha & Omega**, **Axon Enterprise**) and more disruptive changes, such as the sudden resignation of **Lands' End's** top legal and licensing executive. Overall, the period is characterized by high leadership fluidity, with a few filings signaling deep operational or financial challenges that warrant close monitoring.

32 high priority 32 total filings
· daily

USA Insider Trading Pulse — July 10, 2026

Today's insider trading pulse reveals a pronounced bearish tilt, with 11 filings showing negative sentiment from direct sales by senior executives, including C-suite officers at Aktis Oncology, Tempus AI, JFrog, and Insmed. A notable cluster of option exercises paired with immediate stock sales—particularly at Aktis Oncology and Insmed—suggests opportunistic profit-taking rather than a loss of confidence in the business. In contrast, the data shows a significant volume of neutral insider activity, primarily director stock awards and option grants at Planet Labs PBC and Seres Therapeutics, indicating routine compensation rather than conviction buying. A single positive signal stands out: a $40 million debt purchase by a 10% owner at Angel Oak Financial Strategies Income Term Trust, implying strong institutional confidence. Period-over-period comparisons were not available in the filings, limiting trend analysis, but the aggregate insider selling value exceeds $10 million, concentrated in healthcare and technology. The absence of forward-looking guidance or capital allocation changes in the filings suggests a quiet period for most companies, making the insider sales the primary actionable signal.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 10, 2026

The July 10, 2026, filings reveal a bifurcated M&A landscape: large-scale SPAC mergers are being renegotiated downward (Plum/CTR valuation cut ~30%), while smaller SPACs struggle to find targets (Quetta extends for the third time). The most significant sector theme is the aggressive pivot into critical minerals and energy transition assets, with two major lithium-focused SPAC deals (Constellation/HiTech and Plum/CTR) and a gold acquisition by a medical device company (Nu-Med Plus). Capital markets remain open for new SPAC IPOs (Viking and Meridian3 raised $431M combined), but the high number of extensions and valuation resets suggests investor skepticism. The most actionable signal is the Brandywine office disposition, which provides a clean comp for Austin office valuations at ~$733/sq ft. Insider activity is notably absent across all filings, which is a neutral signal but warrants monitoring for post-deal insider transactions. The forward-looking catalyst calendar is rich, with three key dates in the next two weeks: the Constellation/HiTech virtual investor event (July 16), the BurTech unit separation (July 14), and the Quetta extension deadline (August 10).

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 10, 2026

Overnight filings reveal a bifurcated market with aggressive capital deployment in AI infrastructure and semiconductor IPOs contrasting with persistent distress signals in small-cap biotech and real estate. The $26.5B SK hynix IPO dominates, signaling strong investor appetite for AI-related hardware, while EquipmentShare's raised guidance and $500M buyback authorization underscore robust demand in the equipment rental sector. However, multiple small-cap companies (InnSuites, Outlook Therapeutics) face going-concern and delisting risks, and insider selling at Hinge Health and United Therapeutics raises caution. A notable pattern is the surge in capital allocation actions—buybacks, credit facility expansions, and SPAC-related financings—indicating companies are positioning for growth or restructuring. The period-over-period data reveals strong revenue growth at ChipMOS (37.2% YoY) and DXP Enterprises (sales doubling to $2.1B), while Ares Management's preliminary performance income estimate of >$50M (vs $16M YoY) signals a potential inflection in alternative asset manager earnings.

22 high priority 28 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — July 09, 2026

This digest covers $134.3 million in federal construction and infrastructure contracts awarded entirely by civilian agencies (0% defense), with the Department of the Interior accounting for $76.0 million (57%) of the total via two large awards to Blinderman Construction Co Inc and Weeks Marine Inc. The highest-conviction signal is the $38.6 million Blinderman Construction contract for National Park Service cabin and lodge rehabilitation, which is fully funded with $38.2 million already outlayed, indicating strong execution and stable civilian infrastructure spending. A key risk is the $29.0 million G&C FAB-CON, LLC contract with the Department of Veterans Affairs, where only $6.6 million of $29.0 million has been outlayed over six years, signaling potential execution delays or funding constraints. No contracts are defense-related, limiting exposure to DOD budget cycles but tying performance to civilian agency appropriations and continuing resolution risks.

4 total filings
· daily

DHS Homeland Security Contracts — July 09, 2026

This digest covers $393.8 million in civilian Department of Homeland Security (DHS) contract obligations from July 9, 2026, with zero defense-related awards. The dominant theme is stable, labor-intensive support services and IT modernization across DHS agencies, led by CBP, USCIS, ICE, and TSA. The highest-conviction signal is a bullish $53.3 million Dell Federal Systems L.P. award for Coast Guard Microsoft licensing (potential $199.7 million total), indicating strong enterprise IT investment. Key risks include fixed-price execution pressure on GEO Group ($57.5 million) and moderate margin risk from time-and-materials pricing on Deloitte ($67.6 million) and Pluribus Digital ($64.5 million) contracts. Overall, the data points to steady civilian spending with limited disruptive growth catalysts for public companies, except for Dell and GEO Group.

8 total filings
· daily

VA Healthcare & Services Contracts — July 09, 2026

This digest covers a single civilian agency contract from the Department of Veterans Affairs (VA) totaling $28.97 million, with no defense-related awards. The sole award is a firm-fixed-price, Service Disabled Veteran Owned Small Business (SDVOSB) set-aside to G&C FAB-CON, LLC for design-build construction in South Florida, spanning 2018–2024. The highest-conviction signal is neutral: the contract indicates continued VA infrastructure spending and a competitive moat from the set-aside, but only $6.6 million (23%) has been outlayed, implying significant execution risk or delayed funding. Key watch items include the $22.3 million in unspent obligations and the fixed-price structure that could pressure margins if costs overrun.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 09, 2026

This digest covers $140.3 million in civilian HHS contracts awarded between 2018 and 2022, with zero defense exposure. The dominant theme is NIH/NIAID-funded infectious disease and structural biology research, accounting for $51.7 million across two nonprofit awards to Seattle Children's Hospital and Northwestern University, both cost-no-fee with no profit margin. The highest-conviction signal is Spero Therapeutics' $49.2 million BARDA cost-sharing contract, which provides long-term revenue through 2026 but carries medium pricing risk and shared financial burden. A key risk is the lack of competitive moat across all four awards, as none were sole-source or set-aside, leaving incumbents vulnerable at re-compete. Overall, the digest signals stable but low-margin civilian R&D funding, with no direct bullish catalysts for for-profit investors beyond Spero's potential revenue recognition.

4 total filings
· daily

New Federal Contractors — July 09, 2026

This digest covers 30 new federal contractor awards totaling $7.2 billion, with zero defense-related contracts—all awards are from civilian agencies, led by a single $5.63 billion sole-source award to NATIONAL SECURITY TECHNOLOGIES, LLC from the Department of Energy, which accounts for 78% of the aggregate value. Excluding that outlier, the remaining $1.57 billion is spread across 29 contracts averaging $54 million each, with the Department of Homeland Security (DHS) and Department of the Treasury being the most active civilian agencies. The highest-conviction bullish signal is the $63.6 million GDIT task order from GSA FEDSIM (potential $303.3 million), reflecting stable IT modernization demand, while the key risk is the heavy concentration in a single non-competitive DOE award that may not be repeatable. Investors should watch for option exercises on the GDIT and Dell Federal Systems contracts as indicators of sustained civilian IT spending.

30 total filings
· daily

Significant Contract Modifications ($10M+) — July 09, 2026

This digest of 50 significant contract modifications, totaling $7.8 billion, reveals a market dominated by civilian agency spending (92% of contracts) with a single $5.63 billion Department of Energy award to National Security Technologies, LLC accounting for the vast majority of the aggregate value. Outside this outlier, the digest shows a fragmented landscape of mid-sized awards ($25M-$115M) concentrated in IT modernization, environmental remediation, and professional services. The highest-conviction signal is the $5.63B sole-source defense contract to National Security Technologies, though its lack of competitive detail limits actionable insight. A key risk is the high number of contracts (e.g., Management & Training Corporation, Arizona State University) that have already expired or show zero outlays, indicating potential budget execution issues or program terminations. The digest is notably devoid of bearish signals, but the prevalence of fixed-price contracts (over 60% of awards) introduces execution risk for contractors like Impres Technology Solutions and NAPHCARE LLC.

50 total filings
· daily

Contract Deobligations Alert — July 09, 2026

This digest covers 30 government contract deobligations totaling $7.2 billion, all from civilian agencies with zero defense-related awards, reflecting a period dominated by civilian IT modernization, environmental remediation, and infrastructure spending. The highest-conviction signal is the $5.63 billion sole-source award to National Security Technologies, LLC from the Department of Energy, though its bullishness is tempered by limited competitive moat data. Key themes include sustained DHS spending on biometrics and fraud analytics (Pluribus Digital, INADEV), IRS IT infrastructure migration (Impres Technology Solutions), and NASA lunar services (Intuitive Machines). A critical risk is the heavy concentration of awards to private or thinly traded entities, limiting direct public market exposure, while the absence of defense contracts signals a potential CR-related pause in DOD obligations.

30 total filings
· daily

Contract Option Exercises — July 09, 2026

This digest analyzes 50 contract option exercises totaling $7.8 billion, predominantly civilian agency awards (46 of 50), with the Department of Energy's $5.63 billion sole-source award to National Security Technologies, LLC dominating the aggregate value. The highest-conviction bullish signals are concentrated in IT modernization and space exploration, with General Dynamics Information Technology ($63.6M), Dell Federal Systems ($53.3M), and Intuitive Machines ($46.8M) standing out. Key risks include the heavy reliance on a single massive DOE contract skewing sector analysis, and the high proportion of fixed-price contracts (over 60%) that transfer cost risk to contractors. Investors should monitor option exercise announcements for GDIT's ASSIST contract and NASA's CLPS program for Intuitive Machines as key catalysts.

50 total filings
· daily

Federal Professional Services Contracts — July 09, 2026

Over the period of July 09, 2026, six federal professional services contracts totaling $277.2 million were awarded, with only one defense-related award (17% of total value), signaling a civilian-heavy procurement week dominated by the Department of Homeland Security (DHS), which accounted for $148.9 million (54% of aggregate). The highest-conviction signal is Deloitte Consulting's $67.6 million competitive win at CBP, indicating stable demand for program management support, though time-and-materials pricing introduces margin uncertainty. A key risk is the $28.9 million SIGMA Defense Systems award at GSA with zero outlays to date, suggesting near-term revenue recognition delays. No bullish or bearish signals were identified; all six contracts are neutral, reflecting routine, non-transformational spending across civilian agencies.

6 total filings
· daily

Federal IT & Cybersecurity Contracts — July 09, 2026

This digest covers 15 civilian federal IT and cybersecurity contracts totaling $745.2 million, with zero defense-related awards. The dominant theme is civilian agency IT modernization, led by the Department of Homeland Security (three awards totaling $158.5M) and the Department of the Treasury (four awards totaling $160.6M). The highest-conviction bullish signal is General Dynamics Information Technology's $63.6M initial task order (up to $303.3M) from GSA FEDSIM for ASSIST modernization, reflecting a competitively won, low-risk cost-plus contract that strengthens GDIT's backlog. A key risk is the high concentration of small business set-asides (8 of 15 contracts), which limits direct public market exposure and introduces execution risk on fixed-price awards like Impres Technology Solutions' $49.7M VMware-to-Nutanix migration for the IRS.

15 total filings
· daily

All HHS Contracts — July 09, 2026

This digest covers five HHS contracts totaling $165.6 million, all civilian (0% defense-related), with an average signal strength of 4.4/10. The dominant theme is stable, low-risk NIH and BARDA funding for biotechnology R&D and infectious disease research, with Spero Therapeutics ($49.2M) and Technical Resources International ($39.3M base) representing the highest-conviction signals. However, all five contracts are neutral-rated, with no bullish or bearish signals, and three of five are cost-no-fee or cost-sharing, limiting profit upside. Key risk: Spero Therapeutics' cost-sharing structure and Arizona State University's zero-outlay contract suggest potential budget execution or termination risk in BARDA's portfolio.

5 total filings